de Oliveira GS, Ceresr KM, Fernandes BS, Kauer-SantAnna M, Fries GR, Stertz L, et al
Discussion In this study, we observed that 12.9% of the patients with type 2 diabetes concomitant with AKD, who were not treated with GLP-1 RAs, experienced mortality within 5 years after discontinuing dialysis for AKI
[High throughput screening for glutathione S-transferase inhibitors]
Gastroenterologists generally prefer Miralax for GLP-1 users
Most people are cleared for exercise and sexual activity, but many dont feel ready for the latter for a long time
Patients should contact their healthcare provider promptly if they experience: Severe, persistent abdominal pain that worsens or differs from typical bloating Inability to pass gas or have bowel movements (possible obstruction) Persistent vomiting that prevents adequate hydration or medication adherence Unintentional weight loss beyond expected therapeutic effects Blood in stool or black, tarry stools Fever accompanying gastrointestinal symptoms Right upper quadrant pain or yellowing of skin/eyes (possible gallbladder disease) Severe constipation with abdominal distension (possible ileus/obstruction) Signs of dehydration (excessive thirst, dark urine, dizziness) These symptoms may indicate complications such as pancreatitis, gallbladder disease, bowel obstruction, or acute kidney injuryall noted in FDA prescribing information as potential risks